Sort   by:  
 Page size 
MetabolomicsDetermination of mode of action of anti-malalrial drugs using untargeted metabolomics
Not available
ORGANISM(S): Plasmodium falciparum 
ST001033 | MetabolomicsWorkbench
MetabolomicsMetabolomics-based profiling of the mode of action of Pathogen Box compounds in Trypanosoma brucei (part-II)
Not available
ORGANISM(S): Trypanosoma brucei brucei 
ST001275 | MetabolomicsWorkbench
MetabolomicsMetabolomics-based profiling of the mode of action of Pathogen Box compounds in Trypanosoma brucei (part-I)
Not available
ORGANISM(S): Trypanosoma brucei brucei 
ST001274 | MetabolomicsWorkbench
MetabolomicsAn integrated drug repositioning analysis for sarcopenia

Global population aging with increased longevity has incurred a higher prevalence of sarcopenia. Sarcopenia is characterized by age-related muscle/strength loss and is becoming a highly important public health issue. The development of sarcopenia increases the risk of various adverse health outco...

2026-01-09 | MTBLS9582 | MetaboLights
MetabolomicsMetabolomics guides rational development of a simplified cell culture medium for drug screening against Trypanosoma brucei
In vitro culture methods underpin many experimental approaches to biology and drug discovery. The modification of established cell culture methods to be more biologically relevant, or to optimise growth, is traditionally a laborious task. Emerging metabolomics technology enables rapid evaluation of ...
2015-05-14 | MTBLS49 | MetaboLights
GenomicsPraziquantel mode of action and resistance
Praziquantel mode of action and resistance
PRJEB1281 | ENA
MetabolomicsMetabolic Drug Response Phenotyping in Colorectal Cancer Organoids by LC-QTOF-MS
As metabolic rewiring is crucial for cancer cell proliferation, metabolic phenotyping of patient-derived organoids is desirable to identify drug-induced changes and trace metabolic vulnerabilities of tumor subtypes. We established a novel protocol for metabolomic and lipidomic profiling of colorecta...
2021-10-12 | MTBLS2130 | MetaboLights
ProteomicsDecrypting drug actions and protein modifications by dose- and time-resolved chemical proteomics
Measuring dose-dependent effects of drugs on post-translational modifications on a proteome-wide scale reveals how these drugs work in cells. Here, we present a quantitative chemical proteomic approach termed decryptM, able to assess target and pathway engagement as well as the mode of action (MoA)...
ORGANISM(S): Homo sapiens (Human) 
2023-03-17 | PXD037285 | Pride
Kat Screen Drug mode of action Post-translational modifciation Time-resolved Inhibitors Decryptm Proteome-wide Hdac Dose-resolved Kinase 
ProteomicsMManassantin A iTRAQ-SPROX Drug Mode-of-Action
Manassantin A is a natural product that has been isolated from the perennial herb Saururus chinensis Baill and the aquatic plant Saururus cernuus. Manassantin A has been shown to possess potent hypoxia inducible factor 1 alpha (HIF-1α) inhibitory activity in a cell-based assay screen of thousands o...
ORGANISM(S): Homo sapiens (Human) 
2016-07-12 | PXD002304 | Pride
Drug mode-of-action Stability of proteins from rates of oxidation (sprox) Mda-mb-231 Protein-ligand binding interactions Manassantin a Itraq 
GenomicsAccelerating early anti-TB drug discovery by creating mycobacterial indicator strains that predict mode of action [Mycobacterium marinum]
Accelerating early anti-TB drug discovery by creating mycobacterial indicator strains that predict mode of action [Mycobacterium marinum]
PRJNA421833 | ENA
Sort   by:  
 Page size